Multiple sclerosis trials in United Kingdom

In United Kingdom 24 Also abroad 506

14 of 24 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities
Where
Oxford
Age
18 years and over
People
50
Run by
Oxford University Hospitals NHS Trust
See details and how to joinNCT07303582
Phase 3Taking people
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Where
Leeds, London, Sheffield, Swansea
Age
40 years to 70 years
People
400 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00
No phaseTaking people
OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
Where
Birmingham
Age
2 years to 16 years
People
90
Run by
Aston University
See details and how to joinNCT07689682
Phase 1Taking people
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Where
Cambridge, Edinburgh, London, Sheffield
Age
18 years to 60 years
People
24 worldwide
Run by
Autolus Limited
See details and how to joinNCT07139743 · EU 2024-519552-93-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Brighton, Bristol, Coventry, Glasgow, Leeds, London, Nottingham, Romford, Stoke-on-Trent
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 2Taking people
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Where
Cardiff, Glasgow, London, Salford, Swansea, Truro
Age
18 years to 60 years
People
360 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00
Phase 1Taking people
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
Where
London
Age
18 years to 65 years
People
72
Run by
Queen Mary University of London
See details and how to joinNCT03783416
Phase 1Taking people
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Where
Cambridge, London
Age
18 years to 60 years
People
24 worldwide
Run by
AstraZeneca
See details and how to joinNCT07224373
No phaseTaking people
Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis
Where
London
Age
18 years to 99 years
People
1,336
Run by
Queen Mary University of London
See details and how to joinNCT07111637
Phase 2Taking people
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Where
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
Age
18 years to 55 years
People
180 worldwide
Run by
ModernaTX, Inc.
See details and how to joinNCT06735248 · EU 2024-517949-13-00
No phaseTaking people
Hesperidin RCT in MS
Where
Swansea
Age
18 years and over
People
60
Run by
Swansea University
See details and how to joinNCT07452562
Phase 2Taking people
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Where
London
Age
18 years to 55 years
People
40
Run by
Queen Mary University of London
See details and how to joinNCT05418010
No phaseNot yet taking people in United Kingdom
Optimising Access to Vocational Rehabilitation for People With Multiple Sclerosis
Where
Nottingham
Age
18 years to 66 years
People
60
Run by
University of Nottingham
See details and how to joinNCT06966115
No phaseTaking people
Assessing NHS ImplemeNTation of an onlinE Resilience Training Acceptance and Commitment Therapy (ACT) Programme to Prevent Job Loss in Multiple Sclerosis
Where
Leeds
Age
18 years to 66 years
People
300
Run by
The Leeds Teaching Hospitals NHS Trust
See details and how to joinNCT06728956